Harbor Advisors LLC continued to hold its stake in Celgene Corporation (NASDAQ:CELG) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,000 shares of the biopharmaceutical company’s stock at the close of the second quarter. Harbor Advisors LLC’s holdings in Celgene were worth $260,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Thompson Davis & CO. Inc. increased its holdings in shares of Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares in the last quarter. Motco increased its holdings in shares of Celgene by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 159 shares in the last quarter. Penserra Capital Management LLC purchased a new position in shares of Celgene in the 2nd quarter valued at about $129,000. Acropolis Investment Management LLC purchased a new position in shares of Celgene in the 2nd quarter valued at about $144,000. Finally, Rational Advisors LLC purchased a new position in shares of Celgene in the 2nd quarter valued at about $156,000. Institutional investors own 80.17% of the company’s stock.
A number of equities analysts have recently issued reports on the stock. Cann reiterated a “buy” rating and issued a $166.00 price target on shares of Celgene in a report on Wednesday, November 22nd. TheStreet downgraded shares of Celgene from a “b-” rating to a “c+” rating in a report on Friday, November 17th. BMO Capital Markets increased their price target on shares of Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, November 17th. Canaccord Genuity set a $140.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Thursday, November 16th. Finally, Oppenheimer set a $166.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Thursday, November 16th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and an average price target of $139.57.
In other Celgene news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares in the company, valued at $12,110,599.56. The disclosure for this sale can be found here. 0.95% of the stock is owned by company insiders.
Shares of Celgene Corporation (NASDAQ CELG) opened at $102.17 on Thursday. Celgene Corporation has a 12 month low of $94.55 and a 12 month high of $147.17. The stock has a market cap of $80,747.23, a PE ratio of 16.02, a price-to-earnings-growth ratio of 0.79 and a beta of 1.78. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period last year, the company earned $1.58 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. sell-side analysts predict that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Harbor Advisors LLC Has $260,000 Holdings in Celgene Corporation (CELG)” was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thestockobserver.com/2017/12/07/harbor-advisors-llc-has-260000-holdings-in-celgene-corporation-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.